Frederick, MD — June 25, 2026
Stemora Inc., a Maryland-based biotechnology company developing next-generation regenerative therapies for osteoarthritis and cartilage injuries, today announced that it has been awarded a $305,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant.
The award supports Stemora's development of a one-step, intraoperative regenerative therapy designed to restore durable hyaline cartilage by activating the body's own skeletal stem cells (SSCs). The company's platform uses a modular, controlled-release biomaterial system engineered to create a pro-regenerative environment within cartilage defects. This approach offers an innovative advancement to currently available treatment methods limited to long-term pain management, complex cell-based interventions, or partial/total joint replacement.
“We are honored to receive NSF's support as we work to transform the treatment landscape for cartilage injuries. This recognition validates our scientific approach and accelerates our mission to deliver a regenerative therapy that restores joint function and improves quality of life for millions of patients.”
The NSF award will enable Stemora to advance its biomaterial delivery system and evaluate its regenerative potential in translational preclinical models, positioning the company for future development milestones and follow-on funding opportunities.
About Stemora
Stemora Inc. is a regenerative medicine company developing first-in-class therapies that activate endogenous skeletal stem cells to durably restore musculoskeletal tissues. Founded in 2025 and headquartered in Frederick, Maryland, Stemora integrates stem cell biology, biomaterials engineering, and orthopedic medicine to address major unmet needs in osteoarthritis and cartilage repair.
Media Contact
Stemora Inc.
info@stemorabio.com
www.stemorabio.com